Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. 2022

Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
Spire Sciences, Boca Raton, FL.

To evaluate the inhibition of progression of structural joint damage through week 48 in patients with moderately to severely active RA receiving upadacitinib as monotherapy or in combination with MTX. Radiographic progression was assessed in two phase 3 randomized controlled trials. MTX-naïve patients were randomized to upadacitinib 15 or 30 mg once daily or MTX monotherapy (SELECT-EARLY, n = 945), while MTX inadequate responders (IRs) were randomized to upadacitinib 15 mg once daily or adalimumab 40 mg every other week or placebo added to background MTX (SELECT-COMPARE, n = 1629). The mean changes from baseline in modified total Sharp score (mTSS), joint space narrowing and erosion scores were determined. Data were analysed both by linear extrapolation for missing data imputation and treatment switching and as observed. In patients naïve or with limited exposure to MTX (SELECT-EARLY), mean changes from baseline to week 48 in mTSS were 0.03 for upadacitinib 15 mg, 0.14 for upadacitinib 30 mg and 1.00 for MTX based on linear extrapolation (P < 0.001 for both upadacitinib doses vs MTX). Among patients with an inadequate response to MTX (SELECT-COMPARE), the mean change from baseline in mTSS was significantly reduced in the upadacitinib 15 mg plus MTX group vs placebo plus MTX (0.28 vs 1.73; P < 0.001). The mean change from baseline in the adalimumab plus MTX group was 0.39. Upadacitinib monotherapy or in combination with background MTX was effective in inhibiting the progression of structural joint damage through week 48 in MTX-naïve and MTX-IR patients with RA. ClinicalTrials.gov (https://clinicaltrials.gov), NCT02706873 and NCT02629159.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006575 Heterocyclic Compounds, 3-Ring A class of heterocyclic compounds that include a three-ring fused structure. Both aromatic or non-aromatic ring structures are included in this category. Fused Heterocyclic Compounds, Three-Ring,Heterocyclic Cpds, 3 Ring,Three Ring Heterocyclic Compounds,3-Ring Heterocyclic Compounds,Fused Heterocyclic Compounds, Three Ring,Heterocyclic Compounds, 3 Ring
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068879 Adalimumab A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS. Adalimumab-adbm,Adalimumab-atto,Amjevita,Cyltezo,D2E7 Antibody,Humira,Antibody, D2E7
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease

Related Publications

Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
May 2023, Clinical rheumatology,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
February 2023, Rheumatology and therapy,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
May 2019, Der Internist,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
July 2021, Rheumatology (Oxford, England),
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
May 2024, RMD open,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
March 2021, Annals of the rheumatic diseases,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
May 2021, Annals of the rheumatic diseases,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
January 2003, Rheumatology (Oxford, England),
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
January 2023, Rheumatology advances in practice,
Charles G Peterfy, and Vibeke Strand, and Alan Friedman, and Stephen Hall, and Eduardo Mysler, and Patrick Durez, and Xenofon Baraliakos, and Jeffrey V Enejosa, and Tim Shaw, and Yihan Li, and Su Chen, and In-Ho Song
January 2021, Arthritis research & therapy,
Copied contents to your clipboard!